MediWound (MDWD) said Wednesday it has initiated a global phase III trial evaluating EscharEx for the treatment of venous leg ulcers.
The trial will assess the efficacy and safety of EscharEx across 40 sites in the US and Europe, enrolling 216 patients in a randomized, double-blind study, focusing on complete debridement and wound closure, MediWound said.
Patients will undergo up to eight daily applications over two weeks, followed by ten weeks of wound management, the company said, adding that an interim analysis is planned for mid-2026 after 65% of patients have completed treatment.
To support the trial, MediWound said it has partnered with Solventum (SOLV), Molnlycke, and MiMedx Group (MDXG), who will supply advanced products to standardize wound management and enhance patient outcomes across all study sites.
MediWound also said it plans to start a phase II study comparing EscharEx to collagenase in VLU patients in 2025 and a phase II/III trial for diabetic foot ulcers in 2026.
MDWD shares were 1.7% higher in recent trading.
Price: 17.56, Change: +0.30, Percent Change: +1.74
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。